November 29, 2016 / 7:35 AM / a year ago

BRIEF-Oxford Biomedica inks strategic alliance with Orchard Therapeutics

Nov 29 (Reuters) - Oxford Biomedica Plc

* Oxford Biomedica announces a strategic alliance with Orchard Therapeutics

* Will develop and supply lentiviral vectors used by orchard for manufacture of ex-vivo gene therapy products

* Orchard to lead global clinical development and commercialisation of programmes in europe, united states and in other regions

* Will receive a 1.95 pct equity stake in Orchard and will be entitled to royalties Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below